Cymabay Therapeutics Inc (CBAY)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Sujal Shah |
| Employees: | 60 |
| Web site: | cymabay.com |
|
7575 GATEWAY BOULEVARD, SUITE 110, NEWARK, CA, 94560
510-293-8800
| |
• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
-
Formally known as:
- CYMABAY THERAPEUTICS INC. COMMON
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
CymaBay Therapeutics, Inc. focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics.
Please log in first to see chart